Has Grant Williams, MD received payments from drug or device companies?

Yes. Drug and device makers reported $140,994 in general payments to Grant Williams, MD across 388 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Grant Williams, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Grant Williams, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Grant Williams, MD

Hematology & Oncology · Birmingham, ALNPI 1316181241

Payments from drug & device makers

$140,994in general payments, 2019–2025

Across 388 payments — averaging $363.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$64K
E.r. Squibb & Sons, L.L.C.$50K
Ipsen Bioscience Inc.$14K
Array Biopharma Inc$3K
AstraZeneca$2K
Bayer$2K
plus $7K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	39	$63,667
E.r. Squibb & Sons, L.L.C.	13	$49,816
Ipsen Bioscience Inc.	3	$14,475
Array Biopharma Inc	8	$2,621
AstraZeneca(2 entities)	31	$2,014
Bayer	14	$1,649
Novartis	32	$627
Ipsen Biopharmaceuticals, Inc	5	$463
Eisai Inc.	11	$433
AbbVie	14	$378
Merck	17	$340
Genentech USA, Inc.	14	$305
Stemline Therapeutics Inc.	9	$296
Pfizer	18	$285
Seagen Inc.	6	$267
Johnson & Johnson(2 entities)	9	$177
Rigel Pharmaceuticals, Inc.	5	$177
Lilly USA, LLC	6	$167
Regeneron Healthcare Solutions, Inc.	8	$157
GSK	7	$142
Daiichi Sankyo Inc.	7	$139
Incyte Corporation	8	$135
Gilead(2 entities)	6	$125
Advanced Accelerator Applications	1	$124
Sanofi	6	$116
Bristol Myers Squibb	5	$109
Blueprint Medicines Corporation	4	$105
Beone Medicines USA, Inc.	6	$101
Servier Pharmaceuticals LLC	5	$92
Karyopharm Therapeutics Inc.	4	$85
Caris MPI, Inc.	3	$84
Sumitomo Pharma America, Inc.	5	$78
Exelixis Inc.	3	$72
Pharmaessentia USA Corporation	3	$69
Taiho Oncology, Inc.	4	$66
Novocure Inc.	3	$66
Mirati Therapeutics, Inc.	3	$57
Adaptive Biotechnologies Corporation	3	$56
Puma Biotechnology, Inc.	3	$55
Springworks Therapeutics, Inc.	2	$54
Genmab U.S., Inc.	3	$53
Deciphera Pharmaceuticals Inc.	2	$52
Myriad Genetic Laboratories, Inc.	2	$49
Pharmacyclics LLC, An Abbvie Company	3	$49
AVEO Pharmaceuticals, Inc.	2	$46
Sobi, Inc	2	$43
Geron Corporation	2	$42
Agios Pharmaceuticals, Inc.	2	$41
EMD Serono, Inc.	2	$39
Beigene USA, Inc.	2	$36
Sirtex Medical Inc	1	$33
Immunocore Limited	1	$30
Sun Pharmaceutical Industries Inc.	1	$29
Tersera Therapeutics LLC	1	$28
Astellas Pharma US Inc	1	$25
Jazz Pharmaceuticals Inc.	1	$24
Pharmacosmos Therapeutics Inc.	1	$24
Boehringer Ingelheim	1	$23
Fennec Pharmaceuticals, Inc.	1	$23
Coherus Oncology, Inc.	1	$20

How this compares

$140,994 in reported general payments places this provider in the 70th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$58,048

Medicare patients

230

Services billed

545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Birmingham

Luciano CostaBirmingham$32.8M
Amitkumar MehtaBirmingham$18.6M
Erica Stringer-ReasorBirmingham$18.1M
Susan BalBirmingham$11.3M
Pankit VachhaniBirmingham$7.9M
Mehmet AkceBirmingham$5.4M
Mayur NarkhedeBirmingham$4.9M
Christos VaklavasBirmingham$4.9M
Lisle NabellBirmingham$3.3M
Omer JamyBirmingham$2.7M

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →